Ceptaris Therapeutics Adds $15M Debt

Ceptaris Therapeutics Inc. said that it has secured $15 million in venture debt financing from Silicon Valley Bank and Oxford Finance. The company, based in Malvern, Penn., is developing treatments for early stage mycosis fungoides, a type of Cutaneous T-Cell Lymphoma.

PRESS RELEASE
Ceptaris Therapeutics, Inc., a privately held specialty pharmaceutical company, today secured $15 million in venture debt financing from Silicon Valley Bank and Oxford Finance.

 

The New Drug Application (NDA) for Ceptaris’ drug candidate, mechlorethamine gel, is currently undergoing review by the U.S. Food and Drug Administration (FDA) for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL).

 

Ceptaris received $7.5 million at closing and has access to the remaining $7.5 million if the NDA is approved by the FDA. The funding will be used for ongoing operational expenses and preparation for commercialization of its investigational drug, mechlorethamine gel. Ceptaris’ primary venture capital investors include Vivo Ventures, Palo Alto Investors, Burrill & Company, Osage Ventures, Aperture Venture Partners, and BioAdvance.

 

“We are very pleased with our venture debt relationships with both SVB and Oxford and the additional capital it provides Ceptaris for pre- and post-launch activities,” said Stephen Tullman, President and CEO at Ceptaris. “Management has worked with both lending institutions in prior companies, including Ception Therapeutics and Vicept Therapeutics, and we look forward to continuing these relationships.”

 

About Ceptaris Therapeutics

 

Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris’ investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Related Posts

Leave a Reply

PEHUB Community

Join the 12502 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget